Navigation Links
Labopharm to present data on its novel trazodone formulation at three upcoming international medical meetings
Date:9/9/2009

LAVAL, QC, Sept. 9 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced that three separate posters will be presented at three upcoming internationally prestigious medical meetings showcasing data on its novel trazodone formulation.

Two posters will be presented in mid-September, including:

The poster entitled: Modeling and Simulation to Optimize Efficacy and Tolerability for a Once-a-day Trazodone Formulation at the 22nd European College of Neuropsychopharmacology Congress to be held from September 12 to 16, 2009 in Istanbul, Turkey; and,

The poster entitled: Once-daily Trazodone: Overview of Pharmacokinetic Properties, which will be presented at the 2009 American College of Clinical Pharmacology (ACCP) 38th Annual Meeting in San Antonio, Texas from September 13-15, 2009.

In October, during the 61st Institute on Psychiatric Services meeting to be held from October 8 to 11th, 2009 in New York City the poster entitled: A Novel Contramid(R)-based Reformulation of Trazodone in Major Depressive Disorder: Characteristics of Antidepressant Response will be presented.

Complete copies of the three poster presentations will be available on Labopharm's website (www.labopharm.com) at the conclusion of each scientific meeting.

About Labopharm's Novel Trazodone Formulation

Major depressive disorder (MDD) is a common mental illness often characterized by a combination of symptoms that interfere with a person's ability to work, sleep, study, eat, and enjoy once-pleasurable activities. Treating MDD with antidepressants is challenging for physicians because patient response to antidepressant drug therapy varies significantly. Rese
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Glaser Pediatric AIDS Foundation (EGPAF) and the American Cancer ... to essential pain medications for people living with HIV ... Pain initiative, this new partnership will help improve efforts ... the country. , Swaziland has the highest HIV ... of adults ages 15-49 infected. Many of these individuals ...
(Date:7/29/2014)... 2014 Regents Health Resources, a consulting ... brought health care industry veteran Daryl Demonbreun and former ... lead the company’s ambitious plans to grow into a ... been moving along at a steady pace for nearly ... a notch,” says Bob Maier, founder and chief executive ...
(Date:7/29/2014)... Test instruments after processing to assure ... where it matters most – on the surgical ... premium domestic appliances, introduces ProCare Protein Check, a ... cleaned. The ProCare liquid is applied directly to ... After 3 minutes, users visually determine the presence ...
(Date:7/29/2014)... that death rates rise in association with extremely hot ... summer of 2003, for example, resulted in about 22,000 ... Alex-andra Schneider at the Institute of Epidemiology II at ... temperatures on the number of deaths caused by cardiovascular ... and low temperatures in the study. , "Our findings ...
(Date:7/29/2014)... July 29, 2014 Healthcare staffing ... 2014 Nurses of Tomorrow Scholarship Competition winners:, ... Reno, NV ,     Racheal D., Freshman, Cerritos ... Junior, Houston Community College in Houston, TX ... Week, Medical Solutions hosts the Nurses of Tomorrow ...
Breaking Medicine News(10 mins):Health News:New partnership to improve access to essential pain medications for people living with HIV 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Mortality rates increase due to extreme heat and cold 2Health News:Medical Solutions Announces Nurses of Tomorrow Scholarship Winners 2
... veterinarians with a new way to understanding and treating heartworm in ... ... -- Merial today announced the availability of an educational CD for ... of heartworm prevention and treatment in dogs. Launched at the North ...
... As the unemployment rate grows, so do,the numbers ... with the,loss of health insurance. COBRA continuation coverage can ... workers have the right to,purchase such coverage, only about ... high. A November 2008 study by non-profit advocacy group,Families ...
... companies pull products from shelves as FDA advises consumers ... while salmonella probe continues , , MONDAY, Jan. 19 (HealthDay ... peanut butter products continued without letup Monday, as more ... store shelves. , The actions followed a U.S. Food ...
... Jan. 19 The 66th Annual Golden Globe Awards ... smiles this year thanks to the Kari Feinstein,s 2009 ... of the style lounge included Paris Hilton, Jessica Alba ... Kellan Lutz (Emmett Cullen). Proceeds of the lounge supported ...
... Health Innovation Discusses the Impact of the Economic Crisis on ... A new report released today from the ... to health providers, has found that hospitals and health systems ... spending and unprofitable healthcare services as a result of the ...
... Jan. 19 Abbott announced today,that the ... status,under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) ... blood analyzer. , Cartridges for ... a patient,s,metabolic state within a few minutes. The ...
Cached Medicine News:Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 2Health News:Heartworm CD by Merial Offers Unique Approach to Managing this Deadly Condition 3Health News:Is Your Business Ready for the COBRA Premium Subsidy? 2Health News:Peanut Butter Product Recalls Mount 2Health News:Peanut Butter Product Recalls Mount 3Health News:Photos: Opalescence Treswhite Supreme Adds Glimmer to 'Twilight' Film Actor's Smile 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 2Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 3Health News:Hospitals and Health Systems to Cut Back on Both Capital Spending and Unprofitable Services in 2009 4Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 2Health News:Abbott Receives FDA CLIA Waiver for Use of Five Additional Cartridges on the i-STAT Handheld Blood Analyzer 3
(Date:7/29/2014)... and TORONTO ... Acquisitions Corporation (OTCBB: ESAQ), an emerging pharmaceutical ... development of improved novel formulations and alternative ... announces expansion of its pharmaceutical development implementing ... direction includes large molecule drugs that will address ...
(Date:7/29/2014)... , July 29, 2014  Based on ... systems (PERS) market, Frost & Sullivan recognizes MobileHelp ... Award for Price Performance Value Leadership. MobileHelp,s leadership ... captures expectations for tech progression in personal emergency ... for these solutions. MobileHelp is at ...
(Date:7/29/2014)... Medical Corporation (Apex, TWSE: 4106), a leading player in the ... is appealing the judgment of the Regional Court of ... that found the headgear of certain mask models infringe a ... against various ResMed patents in major countries. Apex further reiterates ... ResMed filed the lawsuit with the Regional ...
Breaking Medicine Technology:EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 2EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 3EastGate Acquisitions Announces Expansion of its Pharmaceutical Developments Implementing its Sub-Micron Platform Technology 4Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 2Frost & Sullivan Applauds MobileHelp for its Targeted Supplies for the PERS Market 3Apex Continues Fighting Against Patents to Free Up Competition 2
... 2011 Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: ... and commercialization of products for central nervous system disorders, ... one of Israel,s leading private biotech, pharmaceutical and medical ... Israel. "We are excited to reach this ...
... Cell Therapeutics, Inc. ("CTI") (NASDAQ: CTIC ... that final results from the phase II OPAL study ... acute myeloid leukemia (AML) were presented by Jorge Cortes, ... Center during the Acute Myeloid Leukemia - Therapy, excluding ...
Cached Medicine Technology:Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel 4Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 2Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 3Final OPAL Phase II Results of Tosedostat Demonstrate Significant Response Rates in Elderly Patients with Treatment Refractory or Relapsed Primary or Secondary Acute Myeloid Leukemia (AML) 4
... and removal in the urinary tract. The nitinol ... shape following extreme torsion. The unique tipless design ... basket to open at the base of the ... reduces the likelihood of mucosal damage and perforation. ...
... Used for soft-tissue ... limited to paravaginal repairs, ... or rectocele. Surgisis® ES ... enhanced strength for intraoperative ...
... Used for temporary suprapubic urinary diversion ... puncture the bladder. The access sheath is ... Once the catheter is introduced, the access ... low-profile catheter support is included for external ...
... and a FAM-labeled probe targeting the VP1 gene ... ASR contains primers and a Texas Red-labeled probe ... an instrument that can detect FAM and Texas ... Analyte Specific Reagent* (ASR) program is comprised of ...
Medicine Products: